Mapping dopaminergic deficiencies in the substantia nigra/ventral tegmental area in schizophrenia

Brain Structure and Function

Volumn 221, Issue 1, 2016, Pages 185-201

  Rice, Matthew W ^a   Roberts, Rosalinda C ^b   Melendez Ferro, Miguel ^a,b   Perez Costas, Emma ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Immunohistochemistry; Mesocortical; Mesolimbic; Neuropathology; Neuropsychiatric disorders; Tyrosine hydroxylase

Indexed keywords

TYROSINE 3 MONOOXYGENASE; DOPAMINE;

ADULT; AGED; ARTICLE; BRAIN MAPPING; CELL BODY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; ENZYME DEFICIENCY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITATIVE RESEARCH; SCHIZOPHRENIA; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM; VERY ELDERLY; CELL COUNT; METABOLISM; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CELL COUNT; DOPAMINE; DOPAMINERGIC NEURONS; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE; VENTRAL TEGMENTAL AREA;

EID: 84955076584     PISSN: 18632653     EISSN: 18632661     Source Type: Journal    
DOI: 10.1007/s00429-014-0901-y     Document Type: Article

References (77)

1. Abi-Dargham A, Silstein M, Kegeles L, Laruelle M (2010) Dopamine dysfunction in schizophrenia. In: Iversen LL, Iversen SD, Dunnett SB, Bjorklund A (eds) Dopamine Handbook. Oxford University Press, Oxford, pp 511–519
2. Akil M, Pierri JN, Whitehead RE, Edgar CL, Mohila C, Sampson AR, Lewis DA (1999) Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry 156:1580–1589
3. Akil M, Edgar CL, Pierri JN, Casali S, Lewis DA (2000) Decreased density of tyrosine hydroxylase-immunoreactive axons in the entorhinal cortex of schizophrenic subjects. Biol Psychiatry 47:361–370
4. Bergman O, Hakansson A, Westberg L, Nordenstrom K, Carmine Belin A, Sydow O, Olson L, Holmberg B, Eriksson E, Nissbrandt H (2010) PITX3 polymorphism is associated with early onset Parkinson’s disease. Neurobiol Aging 31:114–117
5. Bogerts B, Hantsch J, Herzer M (1983) A morphometric study of the dopamine-containing cell groups in the mesencephalon of normals, Parkinson patients, and schizophrenics. Biol Psychiatry 18:951–969
6. Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 20:140–144
7. Carlsson A, Lindqvist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180:1200
8. Chung CY, Seo H, Sonntag KC, Brooks A, Lin L, Isacson O (2005) Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum Mol Genet 14:1709–1725
9. Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481–483
10. Damier P, Hirsch EC, Agid Y, Graybiel AM (1999a) The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28 K) immunohistochemistry. Brain 122:1421–1436
11. Damier P, Hirsch EC, Agid Y, Graybiel AM (1999b) The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain 122:1437–1448
12. Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148:1474–1486
13. Fallon JH, Loughlin SE (1987) Monoamine innervation of cerebral cortex and a theory of the role of monoamines in cerebral cortex and basal ganglia. In: Jones EG, Peters A (eds) cerebral cortex. Plenum Press, New York, pp 41–109
14. Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114:2283–2301
15. Finlay JM (2001) Mesoprefrontal dopamine neurons and schizophrenia: role of developmental abnormalities. Schizophr Bull 27:431–442
16. Floresco SB, Magyar O (2006) Mesocortical dopamine modulation of executive functions: beyond working memory. Psychopharmacology 188:567–585
17. Frankle WG, Laruelle M (2002) Neuroreceptor imaging in psychiatric disorders. Ann Nucl Med 16:437–446
18. Fuchs J, Mueller JC, Lichtner P, Schulte C, Munz M, Berg D, Wullner U, Illig T, Sharma M, Gasser T (2009) The transcription factor PITX3 is associated with sporadic Parkinson’s disease. Neurobiol Aging 30:731–738
19. Gaspar P, Stepniewska I, Kaas JH (1992) Topography and collateralization of the dopaminergic projections to motor and lateral prefrontal cortex in owl monkeys. J Comp Neurol 325:1–21
20. Gibb WR, Lees AJ (1991) Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson’s disease. J Neurol Neurosurg Psychiatry 54:388–396
21. Goldman-Rakic PS (1996) Regional and cellular fractionation of working memory. Proc Natl Acad Sci USA 93:13473–13480
22. Grimm J, Mueller A, Hefti F, Rosenthal A (2004) Molecular basis for catecholaminergic neuron diversity. Proc Natl Acad Sci USA 101:13891–13896
23. Grunblatt E, Mandel S, Maor G, Youdim MB (2001) Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson’s disease using cDNA microarray: effect of R-apomorphine. J Neurochem 78:1–12
24. Guillin O, Abi-Dargham A, Laurelle M (2007) Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol 78:1–39
25. Haber SN, Fudge JL (1997) The primate substantia nigra and VTA: integrative circuitry and function. Crit Rev Neurobiol 11:323–342
26. Haber SN, Gdowski MJ (2004) The basal ganglia. In: Paxinos G, Mai JK (eds) The Human Nervous System. Elsevier Academic Press, London, pp 676–738
27. Haber SN, Ryoo H, Cox C, Lu W (1995) Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter: comparison with the mRNA for the D2 receptor, tyrosine hydroxylase and calbindin immunoreactivity. J Comp Neurol 362:400–410
28. Hauser MA, Li YJ, Xu H, Noureddine MA, Shao YS, Gullans SR, Scherzer CR, Jensen RV, McLaurin AC, Gibson JR, Scott BL, Jewett RM, Stenger JE, Schmechel DE, Hulette CM, Vance JM (2005) Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. Arch Neurol 62:917–921
29. Hirsch E, Graybiel AM, Agid AM (1988) Melanized dopaminergic neurons are differentially susceptible to degradation in Parkinson’s disease. Nature 334:345–348
30. Howes OD, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III–the final common pathway. Schizophr Bull 35:549–562
31. Howes OD, Williams M, Ibrahim K, Leung G, Egerton A, McGuire PK, Turkheimer F (2013) Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study. Brain 136:3242–3251
32. Ichinose H, Ohye T, Fujita K, Pantucek F, Lange K, Riederer P, Nagatsu T (1994) Quantification of mRNA of tyrosine hydroxylase and aromatic l-aminoacid decarboxylase in the substantia nigra in Parkinson’s disease and schizophrenia. J Neural Transm Park Dis Dement Sect 8:149–158
33. Kaalund SS, Newburn EN, Ye T, Tao R, Li C, Deep-Soboslay A, Herman MM, Hyde TM, Winberger DR, Lipska BK, Kleinman JE (2013) Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia. Mol Psychiatry. doi:10.1038/mp.2013.165
34. Keshavan MS, Nasrallah HA, Tandon R (2011) Schizophrenia, “Just the Facts” 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse. Schizophr Res 127:3–13
35. Kubis N, Faucheux BA, Ransmayr G, Damier P, Duyckaerts C, Henin D, Forette B, Le Charpentier Y, Hauw JJ, Agid Y, Hirsch EC (2000) Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain 123:366–373
36. Lopez-Garcia P, Young Espinoza L, Molero Santos P, Marin J, Ortuno Sanchez-Pedreno F (2013) Impact of COMT genotype on cognition in schizophrenia spectrum patients and their relatives. Psychiatry Res 208:118–124
37. Luk KC, Rymar VV, van den Munckhof P, Nicolau S, Steriade C, Bifsha P, Drouin J, Sadikot AF (2013) The transcription factor Pitx3 is expressed selectively in midbrain dopaminergic neurons susceptible to neurodegenerative stress. J Neurochem 125:932–943
38. Meyer-Lindenberg A (2010) Imaging genetics of schizophrenia. Dialogues Clin Neurosci 12:449–456
39. Mizoguchi K, Shoji H, Tanaka Y, Maruyama W, Tabira T (2009) Age-related spatial working memory impairment is caused by prefrontal cortical dopaminergic dysfunction in rats. Neuroscience 162:1192–1201
40. Motulsky HJ (2010) Intuitive biostatistics: A nonmathematical guide to statistical thinking. Oxford University Press, New York
41. Motulsky HJ, Brown RE (2006) Detecting outliers when fitting data with nonlinear regression-a new method based on robust nonlinear regression and the false discovery rate. BMC Bioinformatics 7:123
42. Mueller HT, Haroutunian V, Davis KL, Meador-Woodruff JH (2004) Expression of ionotropic gluatamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia. Brain Res Mol Brain Res 121:60–69
43. Nasrallah H, Tandon R, Keshavan M (2011) Beyond the facts in schizophrenia: closing the gaps in diagnosis, pathophysiology, and treatment. Epidemiol Psychiatr Sci 20:317–327
44. Nelander J, Hebsgaard JB, Parmar M (2009) Organization of the human embryonic ventral mesencephalon. Gene Expr Patterns 9:555–561
45. Nieuwenhuys R, Voogd J, van Huijzen C (2008) Topography of spinal cord, brain stem and cerebellum. In: Nieuwenhuys R, Voogd J, van Huijzen C (eds) The human central nervous system. Springer, Berlin, pp 177–246
46. Paxinos G, Huang XF (1995) Atlas of the human brainstem. Academic Press, San Diego
47. Perez-Costas E, Melendez-Ferro M, Roberts RC (2010) Basal ganglia pathology in schizophrenia: dopamine connections and anomalies. J Neurochem 113:287–302
48. Perez-Costas E, Melendez-Ferro M, Rice MW, Conley RR, Roberts RC (2012a) Dopamine pathology in schizophrenia: analysis of total and phosphorylated tyrosine hydroxylase in the substantia nigra. Front Psychiatry 3:31
49. Perez-Costas E, Rodriguez-Pallares J, Roberts RC, Labandeira-Garcia JL, Melendez-Ferro M (2012b) Poly-c-binding proteins in schizophrenia: a possible mechanism for tyrosine hydroxylase pathology. Program No. 452.11. 2012. Neuroscience Meeting Planner. New Orleans, LA: Society for Neuroscience, 2012
50. Puelles L, Verney C (1998) Early neuromeric distribution of tyrosine-hydroxylase-immunoreactive neurons in human embryos. J Comp Neurol 394:283–308
51. Raznahan A, Greenstein D, Lee Y, Long R, Clasen L, Gochman P, Addington A, Giedd JN, Rapoport JL, Gogtay N (2011) Catechol-o-methyl transferase (COMT) val158met polymorphism and adolescent cortical development in patients with childhood-onset schizophrenia, their non-psychotic siblings, and healthy controls. Neuroimage 57:1517–1523
52. Remington G, Agid O, Foussias G (2011) Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment. Expert Rev Neurother 11:589–607
53. Rice MW, Smith KL, Roberts RC, Perez-Costas E, Melendez-Ferro M (2014) Assessment of cytochrome c oxidase dysfunction in the substantia nigra/ventral tegmental area in schizophrenia. PLoS One 9(6):e100054. doi:10.1371/journal.pone.0100054
54. Rudow G, O’Brien R, Savonenko AV, Resnick SM, Zonderman AB, Pletnikova O, Marsh L, Dawson TM, Crain BJ, West MJ, Troncoso JC (2008) Morphometry of the human substantia nigra in ageing and Parkinson’s disease. Acta Neuropathol 115:461–470
55. Seamans JK, Yang CR (2004) The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74:1–58
56. Seeman P (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1:133–152
57. Seeman P, Lee T (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188:1217–1219
58. Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717–719
59. Smidt MP, Burbach JP (2007) How to make a mesodiencephalic dopaminergic neuron. Nat Rev Neurosci 8:21–32
60. Smits SM, Burbach JP, Smidt MP (2006) Developmental origin and fate of meso-diencephalic dopamine neurons. Prog Neurobiol 78:1–16
61. Smits SM, von Oerthel L, Hoekstra EJ, Burbach JP, Smidt MP (2013) Molecular marker differences relate to developmental position and subsets of meso-diencephalic dopaminergic neurons. PLoS One 8(10):e76037
62. Spitzer RL, Williams JB, Gibbon M, First MB (1992) The Structured Clinical Interview for DSM-III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry 49:624–629
63. Surmeier DJ, Guzman JN, Sanchez-Padilla J, Goldberg JA (2010) What causes the death of dopaminergic neurons in Parkinson’s disease? Prog Brain Res 183:59–77
64. Tan HY, Callicott JH, Weinberger DR (2007) Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cereb Cortex 17:171–181
65. Tanaka S (2006) Dopaminergic control of working memory and its relevance to schizophrenia: a circuit dynamics perspective. Neuroscience 139:153–171
66. Thuret S, Bhatt L, O’Leary DD, Simon HH (2004) Identification and developmental analysis of genes expressed by dopaminergic neurons of the substantia nigra pars compacta. Mol Cell Neurosci 25:394–405
67. Toda M, Abi-Dargham A (2007) Dopamine hypothesis of schizophrenia: making sense of it all. Curr Psychiatry Rep 9:329–336
68. Tost H, Hakimi S, Meyer-Lindenberg A (2010) Dopamine dysfunction in schizophrenia: from genetic susceptibility to cognitive impairment. In: Iversen LL, Iversen SD, Dunnett SB, Bjorklund A (eds) Dopamine Handbook. Oxford University Press, Oxford, pp 558–571
69. van den Heuvel DM, Pasterkamp RJ (2008) Getting connected in the dopamine system. Prog Neurobiol 85:75–93
70. van Domburg PH, ten Donkelaar HJ (1991) The human substantia nigra and ventral tegmental area. A neuroanatomical study with notes on aging and aging diseases. Adv Anat Embryol Cell Biol 121:1–132
71. van Os J, Kapur S (2009) Schizophrenia. Lancet 374:635–645
72. Verney C (1999) Distribution of the catecholaminergic neurons in the central nervous system of human embryos and fetuses. Microsc Res Tech 46:24–47
73. Verney C, Zecevic N, Puelles L (2001) Structure of longitudinal brain zones that provide the origin for the substantia nigra and ventral tegmental area in human embryos, as revealed by cytoarchitecture and tyrosine hydroxylase, calretinin, calbindin and GABA immunoreactions. J Comp Neurol 429:22–44
74. Watson RE Jr, Wiegand SJ, Clough RW, Hoffman GE (1986) Use of cryoprotectant to maintain long-term peptide immunoreactivity and tissue morphology. Peptides 7:155–159
75. Williams MR, Galvin K, O’Sullivan B, Macdonald CD, Ching EW, Turkheimer F, Howes OD, Pearce RK, Hirsch SR and Maier M (2013) Neuropathological changes in the substantia nigra in schizophrenia but not depression. Eur Arch Psychiatry Clin Neurosci (In press)
76. Winter S, Dieckmann M, Schwabe K (2009) Dopamine in the prefrontal cortex regulates rats behavioral flexibility to changing reward value. Behav Brain Res 198:206–213
77. Zecevic N, Verney C (1995) Development of the catecholamine neurons in human embryos and fetuses, with special emphasis on the innervation of the cerebral cortex. J Comp Neurol 351:509–535